Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630227 | 0.99 | MET (0.49) | METJAK2MAP4K3ALKAXL | |
| SCHEMBL27630005 | 0.86 | MET (0.53) | METJAK2MAP4K3 | |
| SCHEMBL27650133 | 0.85 | CSF1R (0.44) | METJAK2MAP4K3ALK | |
| SCHEMBL27650155 | 0.80 | MET (0.60) | METJAK2MAP4K3ALK | |
| SCHEMBL487738 | 0.78 | MET (0.53) | METJAK2MAP4K3ALKAXL | |
| SCHEMBL30452923 | 0.78 | MET (0.53) | METJAK2MAP4K3ALKAXL | |
| SCHEMBL27650146 | 0.75 | MET (0.60) | METJAK2MAP4K3 | |
| SCHEMBL3122066 | 0.74 | MET (0.56) | METJAK2MAP4K3ALK | |
| SCHEMBL487937 | 0.74 | MET (0.53) | METJAK2MAP4K3 | |
| SCHEMBL487640 | 0.73 | MET (0.52) | METJAK2MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | claimed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885JAK2 8/4885MAP4K3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.